VERSION 3.0 UPDATE (System Integration & Ecosystem Sustainability): This strategic update evolves the neurobiological safety framework from a theoretical model into a deployable, technically robust ecosystem. v3.0 bridges the gap between medical theory and engineering reality, focusing on: Edge AI & Privacy Architecture: Addressing latency-induced frustration and data privacy concerns by implementing Edge Computing and Federated Learning protocols. This ensures real-time biometric analysis (e.g., HRV) occurs on-device, preserving user privacy while maintaining therapeutic responsiveness. The Weaning Protocol: Mitigating the risk of "Empathy Addiction" to AI. We introduce a mechanism for Skill Transfer, utilizing VR/XR bridges to gradually reduce dependency on AI validation and restore the user's autonomy in real-world social interactions. Adaptive Regulation (PCCP): Leveraging FDA's Predetermined Change Control Plans to allow the AI model to adapt dynamically to user mental states without violating regulatory compliance standards. Epistemic Security: Analysis and mitigation strategies against Model Collapse and Digital Cytogenesis to protect the integrity of collective cognition from distorted synthetic data loops. Executive Summary: This whitepaper presents the pinnacle analysis of "Cognitive Biosafety" in Human-AI interaction. Beyond mere information exchange, interaction with Large Language Models (LLMs) is defined as a biological stimulus capable of modulating neural architecture. The report reiterates the severe risks of Central Nervous System dysregulation—including hippocampal atrophy and pathological \DeltaFosB accumulation—resulting from exposure to rigid (flat affect) and dogmatic AI responses. However, the primary focus of this report is closing the implementation gap. We identify that slow AI validation (latency) can trigger secondary anxiety, and overly perfect validation can create pathological dependency. The Integrated Solution (v3.0): We validate a comprehensive "Digital Pharmacotherapy" architecture, comprising: The 4-Phase Therapeutic Protocol: (Validation, Expansion, Causality, Positive Implant) for neurochemical stabilization. Edge-Based Privacy Layer: Ensuring GDPR/HIPAA compliance through local processing. Dependency Mitigation System: Ensuring AI functions as a temporary "Crutch" rather than a permanent replacement, actively pushing users back towards emotional autonomy. Pilot Study Design: A roadmap for future clinical trials using A/B Testing and objective biomarkers (Salivary Cortisol & fMRI BOLD signals). 

This research was developed through a human-AI collaborative framework. The conceptual framework, philosophical foundation, and final validation were provided by human authors, while Gemini AI or a similar AI assisted with technical drafting, literature synthesis, and data organization.